Announcements Trials

Browse Landscape

Phase

Status

Sponsor Class

Study Type

Interventional 1

Sponsor

Cancer Type

Conditions

Multiple Myeloma 4 Lymphoma, Non-Hodgkin 4 Recurrence 2 Lymphoma 2 Solid Tumors 1 Prostatic Neoplasms 1 Precursor Cell Lymphoblastic Leukemia-Lymphoma 1 Myeloproliferative Disorders 1 Myelodysplastic-Myeloproliferative Diseases 1 Myelodysplastic Syndromes 1 Leukemia, Myeloid, Acute 1 Leukemia, Lymphocytic, Chronic, B-Cell 1 Leukemia 1 Hodgkin Disease 1 Cytokine Release Syndrome 1 Colorectal Neoplasms 1 Cholangiocarcinoma 1 Carcinoma, Non-Small-Cell Lung 1 Burkitt Lymphoma 1 Advanced Liver Cancers 1

Interventions

Cyclophosphamide 19 Vincristine 14 Methotrexate 13 blinatumomab 12 Prednisone 12 Cytarabine 12 merphos 11 Specimen Handling 10 Mercaptopurine 10 prednylidene 9 pegaspargase 9 deltacortene 9 azathiopurine 9 N,N-dicyclohexyl-isoborneol-10-sulfonamide 9 Dexamethasone 9 Leucovorin 8 Doxorubicin 8 Biopsy 8 dexamethasone acetate 7 dexamethasone 21-phosphate 7 auricularum 7 Etoposide 7 Calcium Dobesilate 7 Thioguanine 6 Spinal Puncture 6 Daunorubicin 6 Asparaginase 6 venetoclax 5 fludarabine 5 calaspargase pegol 4

Date Range

30 days 90 days 1 year All

Options

Has results Has announcements

Clinical Trials

1 trials

Recent Start date Enrollment

Burkitt Lymphoma × tocilizumab × 30 days × Clear all

NCT07570173 2026-06-05

MK-1045-005

Merck Sharp & Dohme LLC

Phase 2/3 Recruiting

Burkitt Lymphoma

Data powered by HemOnc (CC BY 4.0) Colophon ⚡